布鲁顿氨酸激酶抑制剂易布鲁替尼和心周吸管:一个案例报告
Mariana Baptista1, Maria Soares1, Rosélia Lima1
1Internal Medicine, Unidade Local de Saúde de Gaia e Espinho, Vila Nova de Gaia, PRT.
Cureus
|February 13, 2026
概括
易布鲁丁尼是B细胞恶性瘤的布鲁顿的氨酸激酶抑制剂,很少会导致心脏坦波纳德. 早期检测和停止使用这种药物对于患者的康复至关重要.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 易布鲁替尼是布鲁顿的氨酸激酶 (BTK) 抑制剂,用于治疗慢性淋巴细胞白血病 (CLL) 等B细胞恶性瘤.
- 心血管不良事件,包括心房动和高血压,是已知的副作用.
- 心周并发症是非常罕见的.
研究的目的:
- 报告与ibrutinib治疗相关的罕见心脏栓塞病例.
- 强调识别和管理这种可能危及生命的并发症的重要性.
主要方法:
- 一个66岁的女性患有CLL,接受IBRUTINIB治疗的病例报告.
- 临床表现包括呼吸障碍,低输液和新发动的心房动.
- 诊断通过心声学证实,显示心脏坦波尼德;用心脏缩术治疗.
主要成果:
- 患者经历了心脏冲压,这是易布鲁替尼的罕见并发症.
- 停止ibrutinib治疗导致输液和临床改善的解决.
- 血液动力学稳定得到了后的心经造术.
结论:
- 心脏吸管是与ibrutinib相关的罕见但严重的不良事件.
- 临床医生应怀疑在接受BTK抑制剂并出现心肺症状的患者心脏吸管.
- 迅速的心声回声和药物停用对于有利的结果至关重要.
相关概念视频
Receptor Tyrosine Kinases
19.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
19.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
561
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
561
Protein Kinases and Phosphatases
15.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Protein Kinases and Phosphatases
4.5K
4.5K
Eukaryotic Transcription Inhibitors
11.1K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
Data Reporting and Recording
5.5K
Reporting and recording are crucial in data documentation. The timely, thorough, and accurate documentation of facts is essential when recording patient data. Failure to record findings during an assessment or interpretation of a problem will result in loss of information and make the patient document unreliable. The reader is left with general impressions if the information is not specific. A recording is documenting data of the individual's health information in a traceable, secure, and...
5.5K


